Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica)

Advice

Following an Independent Review Panel Assessment

pregabalin (Lyrica®) is not recommended for use within NHS Scotland for the treatment of peripheral neuropathic pain in adults.

Comparative clinical and cost effectiveness have not been demonstrated.

Further controlled data are needed to establish its place in therapy in patients refractory to or intolerant of other pharmacological treatments.

Medicine details

Medicine name:: Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica)
SMC ID:: 157/05
Indication:: Peripheral neuropathic pain in adults
Pharmaceutical company: Pfizer Ltd
BNF chapter: Central nervous system
Submission type: IRP
Status: Not recommended
Date advice published: 07 August 2006